Glucagon-like insulinotropic peptides, compositions and methods
    5.
    发明授权
    Glucagon-like insulinotropic peptides, compositions and methods 失效
    胰高血糖素样促胰岛素肽,组合物和方法

    公开(公告)号:US07232879B2

    公开(公告)日:2007-06-19

    申请号:US10769080

    申请日:2004-01-30

    IPC分类号: A61K38/26

    摘要: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

    摘要翻译: 本发明提供由能够与GLP-1分子共沉淀的二价金属阳离子相关联的某些GLP-1分子组成的新型复合物。 要求使用这种复合物来增强B型胰岛细胞中胰岛素表达的药物组合物和方法,以及用于治疗哺乳动物,特别是人类中成熟起始糖尿病的方法。

    Glucagon-like insulinotropic peptides, compositions and methods
    7.
    发明授权
    Glucagon-like insulinotropic peptides, compositions and methods 失效
    胰高血糖素样促胰岛素肽,组合物和方法

    公开(公告)号:US06410513B1

    公开(公告)日:2002-06-25

    申请号:US09573809

    申请日:2000-05-18

    IPC分类号: A61K3800

    摘要: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

    摘要翻译: 本发明提供由能够与GLP-1分子共沉淀的二价金属阳离子相关联的某些GLP-1分子组成的新型复合物。 要求使用这种复合物来增强B型胰岛细胞中胰岛素表达的药物组合物和方法,以及用于治疗哺乳动物,特别是人类中成熟起始糖尿病的方法。

    Human proinsulin pharmaceutical formulations
    8.
    发明授权
    Human proinsulin pharmaceutical formulations 失效
    人胰岛素原药物制剂

    公开(公告)号:US4654324A

    公开(公告)日:1987-03-31

    申请号:US682205

    申请日:1984-12-17

    IPC分类号: A61K38/28 A61K37/00

    CPC分类号: A61K38/28

    摘要: A pharmaceutical composition which comprises human proinsulin in association with a pharmaceutically acceptable carrier is useful in controlling a diabetic condition and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.

    摘要翻译: 包含与药学上可接受的载体结合的人胰岛素原的药物组合物可用于控制糖尿病状况和促进天然激素体内平衡的实现,从而预防或显着减少或延缓糖尿病并发症。

    Pharmaceutical formulations comprising human insulin and human proinsulin
    9.
    发明授权
    Pharmaceutical formulations comprising human insulin and human proinsulin 失效
    包含人胰岛素和人胰岛素原的药物制剂

    公开(公告)号:US4652547A

    公开(公告)日:1987-03-24

    申请号:US682207

    申请日:1984-12-17

    CPC分类号: A61K38/28

    摘要: A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin and human proinsulin in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.

    摘要翻译: 包含与药学上可接受的载体结合的人胰岛素和人胰岛素原的重量比为约1:100至约100:1的药物组合物可用于治疗糖尿病和促进 达到天然激素体内平衡,从而预防或显着减少或延缓糖尿病并发症。

    Pharmaceutical formulations comprising human insulin, human C-peptide,
and human proinsulin
    10.
    发明授权
    Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin 失效
    包含人胰岛素,人C-肽和人胰岛素原的药物制剂

    公开(公告)号:US4652548A

    公开(公告)日:1987-03-24

    申请号:US682204

    申请日:1984-12-17

    IPC分类号: A61K38/28 A61K37/26

    CPC分类号: A61K38/28

    摘要: A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin, human C-peptide, and human proinsulin, said human C-peptide being present in a molar ratio, human insulin to human C-peptide, of from about 1:4 to about 4:1, and said human proinsulin being present in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.

    摘要翻译: 一种药物组合物,其包含与药学上可接受的载体结合的人胰岛素,人C肽和人胰岛素原,所述人C-肽以人胰岛素与人C肽的摩尔比计约为1 :4至约4:1,并且所述人胰岛素原以约1:100至约100:1的重量比存在于人胰岛素原中,可用于治疗糖尿病并促进获得天然激素体内平衡 ,从而防止或显着减少或延缓糖尿病并发症。